Prognostic implications of the EGFR polymorphism rs763317 and clinical variables among young Chinese lung cancer population

Neoplasma. 2023 Jun;70(3):443-450. doi: 10.4149/neo_2023_230305N115.

Abstract

The 5-year survival rate for patients with lung cancer, the world's second most frequent malignant tumor, is less than 20%, and its prognosis cannot be clearly predicted. Our aim was to analyze the epidermal growth factor receptor (EGFR) rs763317 (G>A) single nucleotide polymorphism and its association with prognosis in Chinese Han lung cancer patients. 839 patients with primary lung cancer were recruited, and genomic DNA was extracted and genotyped by SNPscan. Kaplan-Meier technique and multivariate Cox proportional hazards model were used to analyze the association between prognosis and EGFR polymorphism rs763317. A significant association after stratification by age, significantly increased lung cancer risk was associated with the AA homozygous genotype of rs763317 (adjusted hazard ratio = 2.53, 95% CI: 1.31-4.88, p=0.005), and conferred a poor survival for lung cancer patients (MST: median survival time: 13.6 months) compared with GG genotype (MST: 41.5 months), and in the recessive model AA genotype (AA vs. GG + GA; adjusted hazard ratio = 2.57, 95% CI: 1.34-4.93, p=0.004) who were young (<60 years) had a significantly increased risk of death. The EGFR polymorphism rs763617 might serve as a significant genetic marker for predicting the prognosis of lung cancer.

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / genetics
  • East Asian People
  • ErbB Receptors / genetics
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Polymorphism, Single Nucleotide
  • Prognosis

Substances

  • EGFR protein, human
  • ErbB Receptors